GAMMA Investing’s Ocular Therapeutix OCUL Stock Holding History

GAMMA Investing’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.7K	Buy	1,916 +433	+29%	+$4.24K	﹤0.01%	3129
2026 Q2	$14.6K	Sell	1,483 -616	-29%	-$5.58K	﹤0.01%	3016
2026 Q1	$17.8K	Sell	2,099 -60	-3%	-$572	﹤0.01%	2772
2025 Q4	$26.2K	Buy	2,159 +609	+39%	+$7.4K	﹤0.01%	2457
2025 Q3	$18.1K	Sell	1,550 -1	-0.1%	-$12	﹤0.01%	2563
2025 Q2	$14.4K	Buy	1,551 +428	+38%	+$3.35K	﹤0.01%	2630
2025 Q1	$8.23K	Buy	1,123 +1,003	+836%	+$7.71K	﹤0.01%	2845
2024 Q4	$1.02K	Buy	120 +82	+216%	+$800	﹤0.01%	3419
2024 Q3	$331	Buy	+38	New	+$313	﹤0.01%	3444

Other funds holding OCUL

FMN

Financial Management Network Mission Viejo, California $695M AUM 13.16% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

GAMMA Investing's OCUL Position: Q3 2026 in Review

GAMMA Investing increased its Ocular Therapeutix (OCUL) stake by 29% in Q3 2026, buying an estimated $4.24K and bringing the position to 1,916 shares worth $14.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3129.

GAMMA Investing first reported a position in OCUL in Q3 2024 and has held it in 9 quarters since. The position peaked at $26.2K in Q4 2025. 5 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

GAMMA Investing held 1,916 shares of Ocular Therapeutix worth $14.7K as of Q3 2026.
GAMMA Investing bought 433 Ocular Therapeutix shares in Q3 2026, an estimated $4.24K.
Ocular Therapeutix made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3129 holding.
GAMMA Investing first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 9 quarters since.
GAMMA Investing's Ocular Therapeutix position peaked at $26.2K in Q4 2025.
5 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.